secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unity Biotechnology, Inc. (—)
CIK:        0001463361
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0000950170-25-040260
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Unity Bio receives Nasdaq deficiency notice for stockholders' equity below $10M; may face delisting
--------------------------------------------------------------------------------

- Nasdaq notified Unity on March 14, 2025 that stockholders' equity fell below $10M minimum for continued listing (Rule 5450(b)(1)(A)).
- Company must submit a compliance plan by April 28, 2025; if accepted, Nasdaq may grant up to 180 days to cure.
- Unity expects ASPIRE study 24-week data in Q1 2025 and 36-week data in Q2 2025; cash runway into Q4 2025.
- No immediate impact on trading of common stock (UBX); trading continues on Nasdaq Global Select Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1463361/000095017025040260/0000950170-25-040260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1463361/000095017025040260/ubx-20250314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer